MYD88 and myelodysplastic syndrome: The blocking of homodimerization of MYD88 in the CD34 + cells of lower-risk MDS patients led to a 1.6 to 2-fold increase in erythroid and a 30% increase in the total number of colonies; this effect was not observed in high-risk MDS patients [26].